Skip to content
Bomb Report – Lifestyle
Author:
BioNTech SE
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
May 30, 2026
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
May 15, 2026
BioNTech Announces New ADS Repurchase Program
May 7, 2026
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
May 5, 2026
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
April 21, 2026
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
April 11, 2026
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
March 24, 2026
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
March 10, 2026
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
March 10, 2026